More dates

Mind Medicine Australia FREE Webinar - The Strata of States of Consciousness with Dr William (Bill) Richards (USA)

This event has passed Get tickets

Event description

Don’t miss out - Get your tickets early!

Join this FREE WEBINAR presented by Dr William (Bill) Richards (USA).

TOPIC: The Strata of States of Consciousness

You'll learn:

  • The role of psychedelics in encountering and exploring the transcendental realms within us
  • The decision to trust/entrust: Set and Setting
  • Religious Experiences and Religious Lives:  the Challenge of Integration

EVENT DETAILS

  • DATE: 13th March 2024
  • TIME: 11:55am (AEDT) for 12:00pm start, finishing at 1:15pm
  • DURATION: 75 minutes (incl Q&A)
  • LOCATION: Online - a link will be emailed to you with the viewing details


ABOUT THE PRESENTER

Dr William (Bill) Richards (USA)
Psychologist

Dr William A. Richards (Bill), author of Sacred Knowledge: Psychedelics and Religious Experiences, is a Senior Advisor at Sunstone Therapies in Rockville, Maryland (USA), currently focused on the implementation of psychedelic-assisted therapy in palliative care.

Bill also is a psychologist at the Johns Hopkins Center for Psychedelic and Consciousness Research in Baltimore, where he and his colleagues have been pursuing research with psilocybin since 1999, and teaches at the California Institute of Integral Studies and for MMA’s Certificate in Psychedelic-Assisted Therapies. Bill’s graduate degrees encompass the psychology of religion, theology,  comparative religion and clinical psychology.

Bill’s involvement with psychedelic research originated in Germany at the University of Göttingen in 1963. From 1967 to 1977, he pursued research with LSD, DPT, MDA and psilocybin at the Maryland Psychiatric Research Center.


---

MEDICINAL PSYCHEDELIC TREATMENTS

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

SUPPORT PSYCHEDELIC RESEARCH AND THERAPY DEVELOPMENT

Your donation to Mind Medicine Australia will help us accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support. Please click here to make a tax-deductible donation.

DISCLAIMER

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms i.e. Facebook, Instagram or zoom private and public chat forms during the webinar. Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters. Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.


Powered by

Tickets for good, not greed Humanitix donates 100% of profits from booking fees to charity




Refund policy

No refund policy specified.